These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17538548)

  • 21. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.
    Lehman HP; Chen J; Gould AL; Kassekert R; Beninger PR; Carney R; Goldberg M; Goss MA; Kidos K; Sharrar RG; Shields K; Sweet A; Wiholm BE; Honig PK
    Clin Pharmacol Ther; 2007 Aug; 82(2):173-80. PubMed ID: 17507922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
    Tomlin A; Reith D; Dovey S; Tilyard M
    Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.
    Coulter DM
    Drug Saf; 2002; 25(6):433-9. PubMed ID: 12071780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.
    Izem R; Sanchez-Kam M; Ma H; Zink R; Zhao Y
    Ther Innov Regul Sci; 2018 Mar; 52(2):159-169. PubMed ID: 29714520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of consumer reporting on signal detection: using disproportionality analysis.
    Hammond IW; Rich DS; Gibbs TG
    Expert Opin Drug Saf; 2007 Nov; 6(6):705-12. PubMed ID: 17967159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems.
    Dijkstra L; Garling M; Foraita R; Pigeot I
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):396-403. PubMed ID: 32092786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of stratification on adverse drug reaction surveillance.
    Hopstadius J; Norén GN; Bate A; Edwards IR
    Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal detection methodologies to support effective safety management.
    van Manen RP; Fram D; DuMouchel W
    Expert Opin Drug Saf; 2007 Jul; 6(4):451-64. PubMed ID: 17688389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Practical value of active prospective monitoring of drug therapy safety].
    Ovchinnikova EA; Nazimkin KE; Iagudina RI
    Antibiot Khimioter; 2006; 51(9-10):40-6. PubMed ID: 18030790
    [No Abstract]   [Full Text] [Related]  

  • 34. Medical device active surveillance of spontaneous reports: A literature review of signal detection methods.
    Chung G; Etter K; Yoo A
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):369-379. PubMed ID: 32128936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistics: detecting a rare adverse drug reaction using spontaneous reports.
    Schroeder DR
    Reg Anesth Pain Med; 1998; 23(6 Suppl 2):183-9. PubMed ID: 9845392
    [No Abstract]   [Full Text] [Related]  

  • 37. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 38. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implemented data mining and signal management systems on spontaneous reporting systems' databases and their availability to the scientific community - a systematic review.
    de Almeida Vieira Lima LM; Nunes NG; da Silva Dias PG; Marques FJ
    Curr Drug Saf; 2012 Apr; 7(2):170-5. PubMed ID: 22873501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.